182 related articles for article (PubMed ID: 37326105)
21. Chemotherapy of advanced soft-tissue sarcomas in adults.
Pinedo HM; Kenis Y
Cancer Treat Rev; 1977 Jun; 4(2):67-86. PubMed ID: 329988
[No Abstract] [Full Text] [Related]
22. Advances of systemic treatment for adult soft-tissue sarcoma.
Liu W; Jiang Q; Zhou Y
Chin Clin Oncol; 2018 Aug; 7(4):42. PubMed ID: 30173532
[TBL] [Abstract][Full Text] [Related]
23. The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.
Ryan CW; Desai J
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714556
[TBL] [Abstract][Full Text] [Related]
24. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma.
Hornick JL; Dal Cin P; Fletcher CD
Am J Surg Pathol; 2009 Apr; 33(4):542-50. PubMed ID: 19033866
[TBL] [Abstract][Full Text] [Related]
25. Trimodality Treatment of Extremity Soft Tissue Sarcoma: Where Do We Go Now?
Oberoi S; Choy E; Chen YL; Scharschmidt T; Weiss AR
Curr Treat Options Oncol; 2023 Apr; 24(4):300-326. PubMed ID: 36877374
[TBL] [Abstract][Full Text] [Related]
26. Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma.
Harwood JL; Alexander JH; Mayerson JL; Scharschmidt TJ
Orthop Clin North Am; 2015 Oct; 46(4):587-608. PubMed ID: 26410647
[TBL] [Abstract][Full Text] [Related]
27. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
Kopp HG; Patel S; Brücher B; Hartmann JT
Am J Clin Dermatol; 2008; 9(4):207-17. PubMed ID: 18572972
[TBL] [Abstract][Full Text] [Related]
28. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.
Weiss AR; Chen YL; Scharschmidt TJ; Chi YY; Tian J; Black JO; Davis JL; Fanburg-Smith JC; Zambrano E; Anderson J; Arens R; Binitie O; Choy E; Davis JW; Hayes-Jordan A; Kao SC; Kayton ML; Kessel S; Lim R; Meyer WH; Million L; Okuno SH; Ostrenga A; Parisi MT; Pryma DA; Randall RL; Rosen MA; Schlapkohl M; Shulkin BL; Smith EA; Sorger JI; Terezakis S; Hawkins DS; Spunt SL; Wang D
Lancet Oncol; 2020 Aug; 21(8):1110-1122. PubMed ID: 32702309
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic pipeline for soft-tissue sarcoma.
Cassier PA; Labidi-Galy SI; Heudel P; Dutour A; Méeus P; Chelghoum M; Alberti L; Ray-Coquard I; Blay JY
Expert Opin Pharmacother; 2011 Nov; 12(16):2479-91. PubMed ID: 21913865
[TBL] [Abstract][Full Text] [Related]
30. Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments.
Suarez-Kelly LP; Baldi GG; Gronchi A
Expert Opin Pharmacother; 2019 Aug; 20(12):1503-1515. PubMed ID: 31136210
[No Abstract] [Full Text] [Related]
31. Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy.
Charlson J
Curr Treat Options Oncol; 2018 Oct; 19(12):65. PubMed ID: 30361919
[TBL] [Abstract][Full Text] [Related]
32. Pharmacotherapy for pediatric soft-tissue sarcomas.
Casanova M; Ferrari A
Expert Opin Pharmacother; 2011 Mar; 12(4):517-31. PubMed ID: 21306288
[TBL] [Abstract][Full Text] [Related]
33. Current perspectives in the management of soft-tissue sarcoma. The role of chemotherapy in multimodality therapy.
Bramwell VH
Can J Surg; 1988 Nov; 31(6):390-6. PubMed ID: 3052763
[TBL] [Abstract][Full Text] [Related]
34. Clear cell sarcoma: state-of-the art and perspectives.
Wetterwald L; Riggi N; Kyriazoglou A; Dei Tos G; Dei Tos A; Digklia A
Expert Rev Anticancer Ther; 2023 Mar; 23(3):235-242. PubMed ID: 36811446
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621224
[TBL] [Abstract][Full Text] [Related]
36. What's the latest with investigational drugs for soft tissue sarcoma?
Cojocaru E; Napolitano A; Fisher C; Huang P; Jones RL; Thway K
Expert Opin Investig Drugs; 2022 Nov; 31(11):1239-1253. PubMed ID: 36424693
[TBL] [Abstract][Full Text] [Related]
37. Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study.
Tian Z; Dong S; Yang Y; Gao S; Yang Y; Yang J; Zhang P; Wang X; Yao W
BMC Cancer; 2022 Jan; 22(1):56. PubMed ID: 35022029
[TBL] [Abstract][Full Text] [Related]
38. Treatment of adult soft tissue sarcoma: old concepts, new insights, and potential for drug discovery.
Aragon-Ching JB; Maki RG
Cancer Invest; 2012 May; 30(4):300-8. PubMed ID: 22480231
[TBL] [Abstract][Full Text] [Related]
39. Molecularly targeted therapies in adult soft tissue sarcomas: present approach and future directions.
Aranha O; Agulnik M
Expert Opin Ther Targets; 2008 Feb; 12(2):197-207. PubMed ID: 18208368
[TBL] [Abstract][Full Text] [Related]
40. Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology.
Haddox CL; Riedel RF
Expert Rev Anticancer Ther; 2020 Jan; 20(1):5-8. PubMed ID: 31859537
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
